Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

19. März 2026 07:00 ET | Quelle: AC Immune SA

AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026

AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 Initial data indicates significantly higher tracer uptake in patients...
05. März 2026 07:00 ET | Quelle: AC Immune SA

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune to host symposium highlighting Precision Prevention approach to Parkinson's...
04. September 2024 08:00 ET | Quelle: Allyx Therapeutics Inc.

Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated with ALX-001

Allyx Therapeutics first patient first patient has been dosed with its lead compound, ALX-001, in new Parkinson's Disease clinical study
11. März 2024 08:05 ET | Quelle: Allyx Therapeutics Inc.

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients

Allyx Therapeutics Announces Positive Phase 1b Multiple Ascending Dose Data and Advances ALX-001 to Patients